UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2020-09, Vol.31 (9), p.1119-1134

2020

Volltextzugriff (PDF)

Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?

Annals of oncology, 2012-09, Vol.23 Suppl 10, p.x251-x258

Tombal, B

2012

Volltextzugriff (PDF)

Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition?

Annals of oncology, 2015-02, Vol.26 (2), p.257-258

Tombal, B.

2015

Volltextzugriff (PDF)

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Annals of oncology, 2021-06, Vol.32 (6), p.726-735

2021

Volltextzugriff (PDF)

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Annals of oncology, 2015-04, Vol.26 (4), p.743-749

2015

Volltextzugriff (PDF)

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials

Prostate cancer and prostatic diseases, 2017-03, Vol.20 (1), p.110-116

2017

Volltextzugriff (PDF)

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Annals of oncology, 2018-11, Vol.29 (11), p.2200-2207

2018

Volltextzugriff (PDF)

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Annals of oncology, 2013-09, Vol.24 (9), p.2402-2408

2013

Volltextzugriff (PDF)

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL

Annals of oncology, 2016-02, Vol.27 (2), p.286-294

2016

Volltextzugriff (PDF)

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer

Annals of oncology, 2024-03, Vol.35 (3), p.285-292

2024

Volltextzugriff (PDF)

22 Side effects of anti-androgen therapy

Critical reviews in oncology/hematology, 2011, Vol.78, p.S18-S18

Tombal, B

2011

Volltextzugriff (PDF)

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

Prostate cancer and prostatic diseases, 2017-06, Vol.20 (2), p.221-227

2017

Volltextzugriff (PDF)

Bone health in the elderly cancer patient: A SIOG position paper

Cancer treatment reviews, 2016-12, Vol.51, p.46-53

2016

Volltextzugriff (PDF)

MRI for response assessment in metastatic bone disease

European radiology, 2013-07, Vol.23 (7), p.1986-1997

2013

Volltextzugriff (PDF)

MRI for response assessment in metastatic bone disease

European radiology, 2013-07, Vol.23 (7), p.1986-1997

2013

Volltextzugriff (PDF)

Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa)

European radiology, 2010-12, Vol.20 (12), p.2973-2982

2010

Volltextzugriff (PDF)

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer

Prostate cancer and prostatic diseases, 2017-12, Vol.20 (4), p.407-412

2017

Volltextzugriff (PDF)

Ruptured aortic aneurysm due to Mycobacterium bovis BCG with a delayed bacteriological diagnosis due to false negative result of the MPB 64 immunochromatographic assay

BMC research notes, 2017-01, Vol.10 (1), p.64-64, Article 64

2017

Volltextzugriff (PDF)

Focal therapy in prostate cancer-report from a consensus panel

Journal of endourology, 2010-05, Vol.24 (5), p.775-780

2010

Volltextzugriff (PDF)

Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study

Annals of oncology, 2018-10, Vol.29, p.viii278-viii279

2018

Volltextzugriff (PDF)

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist

Scandinavian journal of urology, 2018-11, Vol.52 (5-6), p.349-357

2018

Volltextzugriff (PDF)

Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment

Annals of oncology, 2018-10, Vol.29, p.viii281-viii282

2018

Volltextzugriff (PDF)

Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii288-viii289

2018

Volltextzugriff (PDF)

Prostate volume and its relationship with anthropometric variables among different ethnic groups of South-Kivu, DR Congo

African journal of urology, 2020-12, Vol.26 (1), p.32-7, Article 32

2020

Volltextzugriff (PDF)

ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2018-10, Vol.29, p.viii723-viii723

2018

Volltextzugriff (PDF)

1 – 25 von 347

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(232)
Mit Volltextzugriff
(329)

Publikationsform

Artikel
(347)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(84)
Science & Technology
(84)
Humans
(81)
Urology
(79)
Male
(66)
Urology & Nephrology
(42)
Oncology
(38)
Aged
(35)
Prostate Cancer
(35)
Middle Aged
(30)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Prostatic Neoplasms - Pathology
(21)
Adult
(16)
Aged, 80 And Over
(16)
Nephrology. Urinary Tract Diseases
(16)
Hematology, Oncology And Palliative Medicine
(15)
Tumors Of The Urinary System
(15)
Urinary Tract. Prostate Gland
(15)
Female
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?

Assessing the benefit of bone-targeted therapies in prostate cancer, is the devil in the end point's definition?

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials

Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer

22 Side effects of anti-androgen therapy

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL

Bone health in the elderly cancer patient: A SIOG position paper

MRI for response assessment in metastatic bone disease

MRI for response assessment in metastatic bone disease

Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa)

The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer

Ruptured aortic aneurysm due to Mycobacterium bovis BCG with a delayed bacteriological diagnosis due to false negative result of the MPB 64 immunochromatographic assay

Focal therapy in prostate cancer-report from a consensus panel

Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist

Treatment of metastatic castration-resistant prostate cancer (mCRPC); Survival by type of progression at initiation of treatment

Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC)

Prostate volume and its relationship with anthropometric variables among different ethnic groups of South-Kivu, DR Congo

ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)

Suchergebnisse filtern